Researchers from the DZD found that after weight loss, individuals with overweight and obesity showed an increase in the protein Kallistatin in subcutaneous white adipose tissue. This protein has potential therapeutic benefits for those with obesity and type 2 diabetes. Clinical studies revealed that obese individuals have lower levels of Kallistatin, which plays a role in glucose metabolism and inflammation. Further research demonstrated that Kallistatin can improve liver insulin sensitivity. These findings suggest that Kallistatin could be a promising therapeutic target for treating obesity and insulin resistance, potentially emulating the beneficial effects of weight loss and addressing type 2 diabetes.
Source link
Kallistatin expression increases after weight loss, study reveals
